Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use.
BACKGROUND
Approved indications of intravenous (i.v.) proton pump inhibition (PPI) are limited to treatment of reflux esophagitis in patients unable to tolerate oral medications and for patients with pathologic hypersecretory states.


OBJECTIVE
i.v. PPIs are commonly used after endoscopic evaluation of patients with high-risk endoscopic stigmata (HRES) of nonvariceal upper GI bleeding (NVUGIB). There appears to have been an expansion of indications of this drug at many centers.


METHODS
All consecutive patients receiving i.v. PPI (pantoprazole) between 2 study periods, (1) when pantoprazole was restricted to the gastroenterology service and (2) when it was unrestricted, were reviewed.


METHODS
Tertiary care university hospital.


METHODS
All receiving i.v. PPI.


METHODS
i.v. PPI utilization.


METHODS
Percentage of patients receiving i.v. PPI for indications other than bleeding during 2 time periods.


RESULTS
In the early period, 217 patients (67.30% male) received i.v. PPI on 218 occasions compared with 516 patients (65.31% male, P= .61) in the later period on 613 occasions. In the early group, 93.12% of 217 patients received i.v. PPI for NVUGIB compared with 56.12% of 516 patients (P< .0001) with 18% of patients receiving i.v. PPI for nothing by mouth status and 13% for abdominal pain in the later group. A total of 153 (70.18%) patients in the early group underwent upper endoscopy compared with only 275 (44.86%) patients in the later group; 84 of these 153 patients (54.90%) were already on i.v. PPI at the time of endoscopy in the early group compared with 253 (92.00%, P< .0001).


CONCLUSIONS
i.v. PPI use has escalated at our hospital and is being prescribed in patients before endoscopy with fewer patients noted to have HRES on endoscopy.
Law
Joanna K
JK
Division of Gastroenterology, Department of Medicine, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Andrews
Chris N
CN
Enns
Robert
R
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004363:Drug Utilization; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004945:Esophagoscopy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D010818:Practice Patterns, Physicians' / Q000639:trends; D011292:Premedication; D055656:Prescriptions / Q000706:statistics & numerical data*; D011336:Probability; D054328:Proton Pump Inhibitors; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole